核医学与生物学 SCIE

期刊简介预计审稿时间： 一般,3-8周 约8周

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.

These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

《核医学与生物学》发表涉及放射性药物科学各个方面的原创研究：合成、体外和离体研究、通过解剖或成像进行的体内生物分布、放射性药理学、放射性药理学以及新型靶向放射性示踪剂的转化临床研究。靶标对未满足的临床需求的重要性应是首要考虑因素。如果提交的新型放射性药物合成没有体外或体内数据，则必须强调化学的独特性。

这些多学科研究应验证定位机制，无论探针是基于与受体、酶、肿瘤抗原还是另一个明确定义的靶标的结合。研究应旨在评估化学和放射性药物特性如何影响药代动力学、药效学或治疗效果。理想情况下，研究将解决探针对疾病或治疗变化的敏感性，尽管仅验证机制的研究也是可以接受的。放射性药物学实践涉及制备、自动化、质量控制、分配以及适用于放射性药物对人体的鉴定和管理的法规等问题，是发展过程的一个重要方面，但前提是该研究对该领域有重大影响。

只要标记化合物定位和治疗效果的特异性得到解决，那么关于治疗性放射性药物主题的贡献也是合适的。

《Nuclear Medicine And Biology》(核医学与生物学)编辑部通讯方式为ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。